Inactive Instrument

News Apricus Biosciences Inc Nasdaq

Equities

US03832V3078

Summary

Unlock all the news: Be the first to know and act before the market!

Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	May. 16	PR
Reverse Split: 1 of 8	May. 15	FA
Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	May. 15	CI
Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	May. 14	MT
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split	May. 14	PR
Seelos: Q1 Earnings Snapshot	May. 14	AQ
Seelos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Seelos Therapeutics, Inc. Announces Resignation of Daniel J. O?Connor from the Board	May. 03	CI
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations	Apr. 29	PR
Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors	Apr. 29	CI
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	Mar. 19	MT
Seelos Therapeutics' ALS treatment fails in mid-stage study	Mar. 19	RE
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)	Mar. 19	PR
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)	Mar. 19	CI
Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination	Mar. 04	MT
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	Mar. 03	MT
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	Jan. 29	AQ
Seelos Therapeutics Launches Registered Direct Offering, Concurrent Private Placement	Jan. 26	MT
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	Jan. 26	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Apricus Biosciences Inc Nasdaq

Equities

US03832V3078

Summary

Filters